Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

14.13 -4.07

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

14.18

Chiffres clés
By Trading Economics
Revenu	-4.3M -18M
BPA	-0.19
Employés	37
EBITDA	-5.3M -17M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+108.33% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	61M 1.2B
Ouverture précédente	18.2
Clôture précédente	14.13

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 août 2026, 23:51 UTC

"Bitcoin and Ethereum Rise Amid Market Uncertainty; Barclays Warns of Commodity Shock, Fed Signals Possible Rate Hikes, and Canada's GDP Growth Falls Short of Expectations."

29 août 2026, 23:51 UTC

Bitcoin and Ethereum rise amid economic uncertainties, while Barclays warns of a commodity shock and Fed Chair hints at potential interest rate hikes.

29 août 2026, 23:51 UTC

Cryptocurrency gains amid economic uncertainty; Barclays warns of commodity shock from El Niño, while Fed signals potential rate hikes and Canada faces trade tensions.

29 août 2026, 23:51 UTC

Cryptocurrency gains amid economic uncertainty, while Barclays warns of commodity shocks and Fed signals potential rate hikes, impacting U.S. stock markets and Canadian trade tensions.

29 août 2026, 23:41 UTC

U.S. Import Data Release on September 3, 2026 Expected to Reflect Impact of Tariff Changes Amid Escalating Trade Tensions with Canada.

29 août 2026, 23:41 UTC

U.S. Trade Deficit Expected to Widen to $86.4 Billion Amid Ongoing Tariff Tensions with Canada

29 août 2026, 23:41 UTC

Mexican Business Confidence Remains Low Ahead of September Survey, Anticipating Continued Economic Challenges

29 août 2026, 23:41 UTC

U.S. July 2026 export data release on September 3 expected to reflect ongoing trade challenges amid U.S.-Canada tariff tensions, raising market volatility concerns.

29 août 2026, 23:41 UTC

Canada's Balance of Trade Expected to Show C$3.2 Billion Surplus Amid Rising U.S.-Canada Tariff Tensions

29 août 2026, 23:31 UTC

Brazil's Q2 2026 GDP Growth Rate Release on September 1st Sparks Cautious Optimism Amid Economic Challenges and Global Trade Tensions.

29 août 2026, 23:31 UTC

South Africa's Balance of Trade report on August 31 expected to reveal if trade surplus continues amid concerns over El Niño impacts and global commodity markets.

29 août 2026, 23:11 UTC

ADP Employment Change report on September 2 forecasts a modest increase of 47,000 jobs amid cautious labor market sentiment and potential downward revisions in nonfarm payrolls.

29 août 2026, 23:11 UTC

Mexican Consumer Confidence Index Set for Release on September 3, Amid Global Economic Uncertainty and Mixed Sentiments.

29 août 2026, 23:01 UTC

Macro News

DAX 30 Index declines in after-market hours, pressured by hawkish Fed remarks and geopolitical tensions. The index remains near its one-month low.

29 août 2026, 22:52 UTC

Japan's Household Spending Data Release Sparks Caution Amid Rising Inflation Concerns and Weak Investor Confidence

29 août 2026, 22:52 UTC

Japan's Household Spending Expected to Decline by -1.6% YoY Amid Inflation Concerns and Weak Consumer Sentiment

29 août 2026, 22:52 UTC

Brazil's Q2 GDP Growth Rate Release on September 1, 2026, Sparks Cautious Market Anticipation Amid Global Economic Uncertainties.

29 août 2026, 22:51 UTC

Correlated Moves

Barclays reports a potential commodity shock from adverse weather and underinvestment. In after-market trading, Silver Ounce vs Euro is roughly flat near its one-month range.

29 août 2026, 22:41 UTC

Upcoming MBA Mortgage Rate Release Sparks Cautious Investor Sentiment Amid Inflation and Fed Hike Expectations

29 août 2026, 22:11 UTC

Germany's Inflation Rate Expected to Rise to 2.9% in August Amid Fed Concerns Over Elevated Prices

29 août 2026, 22:11 UTC

Germany's Inflation Rate Release on August 31 Sparks Investor Caution Amid Persistent Price Pressures and Potential Monetary Policy Tightening.

29 août 2026, 22:11 UTC

Japan's Q2 2026 Capital Spending YoY data set for release, with a modest growth forecast of 0.2% amid cautious investor sentiment and rising inflation concerns.

29 août 2026, 21:51 UTC

Japan's Industrial Production Expected to Contract 0.006% in July Amid Mixed Economic Sentiment and Rising Inflation Concerns

29 août 2026, 21:51 UTC

Japan's Retail Sales YoY data for July 2026 expected to rise by 0.3% amid mixed economic signals and wavering investor confidence ahead of the release on August 30, 2026.

29 août 2026, 21:41 UTC

South Africa's Business Confidence Index set for release amid cautious market sentiment following significant declines and ongoing geopolitical uncertainties.

29 août 2026, 21:41 UTC

Australia's Ai Group Industry Index set for release on September 1, 2026, amid cautious expectations of continued industrial contraction due to high costs and subdued demand.

29 août 2026, 21:41 UTC

South Korea's Upcoming Inflation Rate Release on September 1, 2026, Expected to Impact Economic Outlook Amid Mixed Market Sentiment and Global Price Pressures.

29 août 2026, 21:31 UTC

API Crude Oil Stock Change Data Release on September 1, 2026, Expected to Impact U.S. Market Amid Rising Inventories and Geopolitical Tensions

29 août 2026, 20:41 UTC

India's Q2 2026 GDP Growth Rate Forecast at 7.1% Amid Cautious Optimism and Global Economic Pressures

29 août 2026, 20:31 UTC

Euro Area Retail Sales Expected to Rise 0.3% in July Amid Mixed Economic Signals and Caution from Spain's Decline

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

108.33% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD 108.33%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.